Welcome to LookChem.com Sign In|Join Free

CAS

  • or
methyl (3R)-3-cyclopropyl-3-(3-hydroxyphenyl)propanoate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1142223-06-0

Post Buying Request

1142223-06-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1142223-06-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1142223-06-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,4,2,2,2 and 3 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1142223-06:
(9*1)+(8*1)+(7*4)+(6*2)+(5*2)+(4*2)+(3*3)+(2*0)+(1*6)=90
90 % 10 = 0
So 1142223-06-0 is a valid CAS Registry Number.

1142223-06-0Downstream Products

1142223-06-0Relevant articles and documents

Design and Synthesis of Novel, Selective GPR40 AgoPAMs

Plummer, Christopher W.,Clements, Matthew J.,Chen, Helen,Rajagopalan, Murali,Josien, Hubert,Hagmann, William K.,Miller, Michael,Trujillo, Maria E.,Kirkland, Melissa,Kosinski, Daniel,Mane, Joel,Pachanski, Michele,Cheewatrakoolpong, Boonlert,Nolting, Andrew F.,Orr, Robert,Christensen, Melodie,Campeau, Louis-Charles,Wright, Michael J.,Bugianesi, Randal,Souza, Sarah,Zhang, Xiaoping,Di Salvo, Jerry,Weinglass, Adam B.,Tschirret-Guth, Richard,Nargund, Ravi,Howard, Andrew D.,Colletti, Steven L.

, p. 221 - 226 (2017)

GPR40 is a G-protein-coupled receptor expressed primarily in pancreatic islets and intestinal L-cells that has been a target of significant recent therapeutic interest for type II diabetes. Activation of GPR40 by partial agonists elicits insulin secretion

ANTIDIABETIC BICYCLIC COMPOUNDS

-

Page/Page column 105, (2014/09/03)

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Discovery of AM-1638: A potent and orally bioavailable GPR40/FFA1 full agonist

Brown, Sean P.,Dransfield, Paul J.,Vimolratana, Marc,Jiao, Xianyun,Zhu, Liusheng,Pattaropong, Vatee,Sun, Ying,Liu, Jinqian,Luo, Jian,Zhang, Jane,Wong, Simon,Zhuang, Run,Guo, Qi,Li, Frank,Medina, Julio C.,Swaminath, Gayathri,Lin, Daniel C.-H.,Houze, Jonathan B.

, p. 726 - 730 (2012/10/30)

GPR40 (FFA1) is a G-protein-coupled receptor, primarily expressed in pancreatic islets, the activation of which elicits increased insulin secretion only in the presence of elevated glucose levels. A potent, orally bioavailable small molecule GPR40 agonist

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1142223-06-0